Over 1950 New Jersey Auctions End Today - Bid Now
Over 60 Total Lots Up For Auction at Two Locations - Over 250 North Carolina Auctions End Tomorrow 10/04 - Bid Now, CA 10/05

Cleerly partners with ProScan Imaging to transform the standard of care for heart disease prevention

Press releases may be edited for formatting or style | June 02, 2023 Artificial Intelligence Cardiology CT X-Ray
DENVER – May 31, 2023 — Cleerly, the company creating a new standard of care for heart disease, announced today a partnership with ProScan Imaging to offer more personalized approaches to heart health, cardiovascular analyses, and treatment plans. ProScan Imaging is recognized as being at the forefront of using new imaging technology to deliver the best possible care to its patients. The company plans to use Cleerly’s AI-enabled platform to evaluate coronary computed tomography angiography (CCTA) imaging, allowing radiologists and cardiologists to identify, characterize and qualify atherosclerosis (plaque) buildup in the walls of heart arteries more easily. The personalized reporting provided through this platform allows providers to deliver precision treatment across the continuum of heart disease severity, improving clinical outcomes while drastically reducing costs.

“We are thrilled to be partnering with ProScan Imaging on their mission to deliver the best possible diagnostic care to their patients,” said James K. Min, MD, FACC, FESC, MSCCT, founder and CEO of Cleerly. “This partnership will allow us to improve heart health through a personalized approach to evaluating patients’ heart disease risk and continue to support Cleerly’s mission to create a world without heart attacks.”

Cleerly’s comprehensive coronary analysis provides actionable insights for physicians that go beyond traditional CCTA scans with detailed vessel-by-vessel evaluation of stenoses and atherosclerosis. Its heart disease technologies serve as an all-in-one comprehensive, coronary artery disease (CAD) evaluation solution. For every artery and its branches, Cleerly’s technologies accurately and precisely quantify atherosclerosis, vascular morphology, and assess vascular profiling. Through its four-tiered, atherosclerosis plaque-burden staging system, Cleerly describes patients based on total plaque volume or percent atheroma volume with stages that range from normal, mild, moderate, to severe plaque. Additionally, Cleerly evaluates changes in plaque burden through longitudinal disease tracking of changes in CAD over time.
DOTmed text ad

Source-Ray, Inc. - Innovations In Portable X-Ray

SRI is a leading Developer, Manufacturer & Supplier of Innovative Portable Imaging Equipment. We offer Lightweight, Agile, Easy to Maneuver Portable X-Ray Systems ideal for maneuvering in tight spaces. Call us at 631-244-8200

These diagnostic tools and reporting solutions are tailored to all stakeholders in the heart care pathway – be they radiologists, cardiologists, primary care physicians, or patients and their caregivers. ProScan Imaging is one of the largest outpatient imaging networks in the country, with 33 centers in five regions, including Ohio, Indiana, Kentucky, New York and Florida. Upon launch, Cleerly services will be available in ProScan’s largest markets: Cincinnati, OH and Naples, FL imaging centers. This partnership will provide ProScan Imaging access to Cleerly’s care pathway to care for patients across the entire continuum of disease presentation – from early diagnosis of heart disease to ensuring that ongoing treatments are effective for those who have elevated risk of symptoms.

“This new partnership with Cleerly supports our mission to provide the highest-quality diagnostic care to patients,” said Stephen J. Pomeranz, MD, Medical Director and CEO of ProScan Imaging. “We are passionate about empowering patients and providers to make proactive and well-informed medical decisions, and the Cleerly analysis provides the insight needed to make better choices for heart health.”

About Cleerly
Cleerly is the company creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly helps enable comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway.

You Must Be Logged In To Post A Comment